Heska Corporation (HSKA)

NASDAQ: HSKA · IEX Real-Time Price · USD
89.10
+1.55 (1.77%)
At close: Aug 8, 2022 4:00 PM
87.00
-2.10 (-2.36%)
After-hours: Aug 8, 2022 4:17 PM EDT
1.77%
Market Cap 961.44M
Revenue (ttm) 258.04M
Net Income (ttm) -13.01M
Shares Out 10.79M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE 232.56
Dividend n/a
Ex-Dividend Date n/a
Volume 150,987
Open 86.00
Previous Close 87.55
Day's Range 85.53 - 93.79
52-Week Range 79.86 - 275.94
Beta 1.49
Analysts Buy
Price Target 148.16 (+66.3%)
Earnings Date Aug 8, 2022

About HSKA

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measur... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 30, 1997
CEO Kevin Wilson
Employees 655
Stock Exchange NASDAQ
Ticker Symbol HSKA
Full Company Profile

Financial Performance

In 2021, Heska's revenue was $253.74 million, an increase of 28.59% compared to the previous year's $197.32 million. Losses were -$1.15 million, -92.03% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for HSKA stock is "Buy." The 12-month stock price forecast is 148.16, which is an increase of 66.29% from the latest price.

Price Target
$148.16
(66.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Heska (HSKA) Q2 Earnings and Revenues Miss Estimates

Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

5 Toxic Stocks That May Prove Hazardous for Your Portfolio

Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio.

Other symbols: CSLVSTNDM

Heska Corporation Reports Second Quarter 2022 Results

LOVELAND, Colo. , Aug. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported f...

Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for

Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heska Second Quarter 2022 Financial Results and Earnings Call Scheduled for August 8, 2022

LOVELAND, Colo. , July 20, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will repo...

Heska to Present at the Upcoming Stifel 2022 Jaws and Paws Conference

LOVELAND, Colo. , May 25, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced ...

Heska (HSKA) Misses Q1 Earnings and Revenue Estimates

Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska Corporation Reports First Quarter 2022 Results

Quarterly Revenue Up 7% (10% in Constant Currency), Gross Margin Up 290 bps North America POC Lab Consumables Up 10%, Full Year Outlook Reiterated LOVELAND, Colo. , May 9, 2022 /PRNewswire/ -- Heska Cor...

Earnings Preview: Heska (HSKA) Q1 Earnings Expected to Decline

Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heska to Host Virtual 2022 Investor Day on May 17, 2022

LOVELAND, Colo. , April 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, plans to...

Heska First Quarter 2022 Financial Results and Earnings Call Scheduled for May 9, 2022

LOVELAND, Colo. , April 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will rep...

Heska Announces its Annual Meeting of Stockholders on May 4, 2022

LOVELAND, Colo. , April 14, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announc...

Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Ca...

LOVELAND, Colo. , March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and li...

Other symbols: VNRX

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Canc...

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and lic...

Other symbols: VNRX

Heska (HSKA) Tops Q4 Earnings and Revenue Estimates

Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Heska Corporation Reports Fourth Quarter and Full Year 2021 Results

LOVELAND, Colo., Feb. 28, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, reported financ...

Why Earnings Season Could Be Great for Heska (HSKA)

Heska (HSKA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Heska (HSKA) Expected to Beat Earnings Estimates: Should You Buy?

Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heska Fourth Quarter and Full Year 2021 Financial Results and Earnings Call Scheduled for February 28, 2022

LOVELAND, Colo., Jan. 31, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solution...

Heska Corporation Completes Acquisition of VetZ GmbH to Become European Leader in Practice Management Software Solutions

LOVELAND, Colo., Jan. 3, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions...

Heska to Present at the Upcoming Annual J.P. Morgan Health Care Conference

LOVELAND, Colo., Dec. 28, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, anno...

Heska Corporation Reports Third Quarter 2021 Results

LOVELAND, Colo., Nov. 4, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading provider of advanced veterinary diagnostic and specialty products, reported financial resu...

Heska Corporation to Acquire VetZ GmbH, European Leader in Practice Information Management Software Solutions

LOVELAND, Colo., Nov. 2, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, annou...

7 A-Rated Healthcare Stocks to Buy for the Long Haul

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared...

Research opinion: Heska Corp is a ‘strong sell'

Shares of Heska Corp (NASDAQ: HSKA) have lost nearly 20% since late August, but Spruce Point Capital Management says the stock could crash another 60% from here as its current premium valuation is “nons...